Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLDSX8)

Drug Name

TT-30 Drug Info

Synonyms

CR2/factor H modulator (fusion protein, autoimmune/inflammatory disease), Alexion; CR2/factor H modulator (fusion protein, autoimmune/inflammatory disease), Taligen

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Phase 1	[1]

Cross-matching ID

TTD Drug ID: DMLDSX8

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Complement factor H (CFH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trumenba	DMDHCK9	Meningitis	1D01	Approved	[3]
GT103	DMX2J57	Non-small-cell lung cancer	2C25.Y	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Complement factor H (CFH)	TTUW6OP	CFAH_HUMAN	Modulator	[2]
Complement receptor type 2 (CD21)	TT0HUN7	CR2_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01335165) Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH). U.S. National Institutes of Health.
2	The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28;119(26):6307-16.
3	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4	Clinical pipeline report, company report or official report of Grid Therapeutics.